【レポートの概要（一部）】
1. Report Overview
1.1 Introduction to the Diabetes Industry and Market
1.2 Main Report Findings
1.3 This Study Provides the Following Knowledge
1.4 Why You Should Read This Report
1.5 How This Report Delivers
1.6 Main Questions Answered by This Study
1.7 Who is This Study For?
1.8 Research Methods and Analysis
1.9 Frequently Asked Questions (FAQ)
1.10 Associated Visiongain Reports
1.11 About Visiongain
2. Global Diabetes Drugs Market: Introduction
2.1 World Diabetes Drugs Market Segmentation
2.2 What is Diabetes?
2.3 How is Diabetes Classified?
2.4 Risk Factors, Disease Symptoms and Complications
2.5 Criteria for the Diagnosis of Diabetes
2.6 World and Regional Diabetes Incidence and Prevalence
2.7 The Economic Burden of Diabetes
2.8 Unmet Need
2.9 Leading Classes of Diabetic Medications
2.9.1 Type 1 Medication
2.9.1.1 Insulin
2.9.1.2 Surgical Options
2.9.2 Type 2 Medication
2.9.2.1 Alpha-glucosidase Inhibitors
2.9.2.2 Biguanides
2.9.2.3 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
2.9.2.4 Sodium-Glucose Co-Transporter 2 (SGLT2)
2.9.2.5 Thiazolidinediones
2.9.2.6 Sulfonylureas
2.9.2.7 Meglitinides
2.9.2.8 Other Injectable Medications
2.9.2.9 Combination Drug Therapies for Type 2 Diabetes
3. The World Diabetes Drugs Market, 2016-2026
3.1 The World Diabetes Drug Market, 2015
3.1.1 Diabetes Treatment Market by Drug Class, 2015
3.1.2 Top Selling Diabetes Drugs, 2015
3.1.3 Generic Anti-Diabetes Drugs, 2015
3.2 World Diabetes Drugs Market: Revenue Forecast, 2016-2026
3.3 Injectable and Non-injectable Diabetes Drugs, 2016-2026
3.3.1 Injectable Diabetes Drugs Revenue Forecast, 2016-2026
3.3.2 Non-Injectable Diabetes Drugs Revenue Forecast, 2016-2026
4. Human Insulin and Analogues, 2016-2026
4.1 Insulin and Insulin Analogues Drugs, 2015
4.2 Insulin and Insulin Analogues: Revenue Forecast, 2016-2026
4.3 Insulin and Insulin Analogues: Market Trends, 2016-2026
4.3.1 Will the Top 3 Insulin Producers Sustain Their Market Dominance?
4.3.2 New Opportunities for Biosimilar Insulin: Is the Era of Biosimilar Insulin Coming?
4.4 Lantus (Insulin Aspart, Novo Nordisk): Revenue Forecast, 2016-2026
4.5 NovoLog (Insulin Aspart; Novo Nordisk): Revenue Forecast, 2016-2026
4.6 Humalog (Insulin Lispro; Eli Lilly): Revenue Forecast, 2016-2026
4.7 Levemir (Insulin Detemir; Novo Nordisk): Revenue Forecast, 2016-2026
4.8 Human Insulins (Novo Nordisk): Revenue Forecast, 2016-2026
4.9 NovoMix (Insulin Aspart; Novo Nordisk): Revenue Forecast, 2016-2026
4.10 Humulin (Insulin Isophane; Eli Lilly): Revenue Forecast, 2016-2026
5. Dipeptidyl Peptidase-4 Inhibitors (DPP-4) Market, 2016-2026
5.1 DPP-4 Market, 2015
5.2 DPP-4 Inhibitors Revenue Forecast, 2016-2026
5.3 Januvia (Sitagliptin; Merck (MSD)): Revenue Forecast, 2016-2026
5.4 Janumet (Sitagliptin and Metaformin; Merck & Co.): Revenue Forecast, 2016-2026
5.5 Galvus (Vildagliptin; Novartis): Revenue Forecast, 2016-2026
5.6 Onglyza (Saxagliptin; AstraZeneca): Revenue Forecast, 2016-2026
5.7 Nesina (Alogliptin; Takeda/Furiex Pharmaceuticals): Revenue Forecast, 2016-2026
5.8 Tradjenta (Linagliptin; Eli Lilly and Boehringer Ingelheim): Revenue Forecast, 2016-2026
6. Sulfonylureas Market, 2016-2026
6.1 Sulfonylureas Market, 2015
6.2 Sulfonylureas: Revenue Forecast 2016-2026
6.3 Sulfonylureas: Market Trends 2016-2026
6.3.1 New Opportunites for Sulfonylureas in Emerging Markets
6.3.2 Side Effects and Competitor Drugs Will Affect Sales
6.4 Diamicron (Gliclazide; Servier): Revenue Forecast, 2016-2026
6.5 Amaryl (Glimepiride; Sanofi): Revenue Forecast, 2016-2026
6.6 Glucotrol XL (Glipizide; Pfizer): Revenue Forecast, 2016-2026
7. Glucagon-Like Peptide-1 (GLP-1) Receptor agonists Market, 2016-2026
7.1 GLP-1 Receptor agonists Market, 2015
7.2 GLP-1 Receptor Agonists Revenue Forecast, 2016-2026
7.2.1 GLP-1 Receptor Agonists: Market Trends, 2016-2026
7.2.2 Promising New Approvals in the GLP-1 Class
7.2.3 GLP-1 Agonists and Weight Loss Results May Boost Revenues
7.3 Victoza (Liraglutide; Novo Nordisk): Revenue Forecast, 2016-2026
7.4 Byetta (Exenatide; AstraZeneca): Revenue Forecast, 2016-2026
7.5 Bydureon (Exenatide; AstraZeneca): Revenue Forecast, 2016-2026
8. Alpha-glucosidase Inhibitors Market, 2016-2026
8.1 Alpha-glucosidase Inhibitors Market, 2015
8.2 Alpha-glucosidase Inhibitors: Revenue Forecast, 2016-2026
8.2.1 Alpha-glucosidase Inhibitors: Market Trends, 2016-2026
8.2.1.1 Decline of Alpha-glucosidase Inhibitors Sales Due to Side Effects
8.2.1.2 Is a New Generation of Alpha-glucosidase Inhibitors Worthwhile?
8.3 Glucobay (Acarbose; Bayer AG): Revenue Forecast, 2016-2026
8.4 Basen (Voglibose; Takeda): Revenue Forecast, 2016-2026
8.5 Glyset (Miglitol; Pfizer): Revenue Forecast, 2016-2026
9. Meglitinides Market, 2016-2026
9.1 Meglitinides Market, 2015
9.2 Meglitinides: Revenue Forecast, 2016-2026
9.2.1 Meglitinides: Market Trends, 2016-2026
9.2.1.1 Combination Therapy: New Future for Meglitinides?
9.3 Prandin (Repaglinide; Novo Nordisk): Revenue Forecast, 2016-2026
9.4 Starlix (Nateglinide; Novartis): Revenue Forecast, 2016-2026
9.5 Glufast (Acarbose; Eisai): Revenue Forecast, 2016-2026
10. Thiazolidinediones Market, 2015
11. Sodium – glucose Co-transporter (SGLT2) Inhibitors Market, 2016-2026
11.1 SGLT2 Inhibitors Market, 2015
11.2 SGLT2 Revenue Forecast, 2016-2026
11.2.1 SGLT2 Market Trends, 2016-2026
11.3 Invokana (Canagliflozin; Johnson & Johnson): Revenue Forecast, 2016-2026
11.4 Forxiga (Dapagliflozin; AstraZeneca): Revenue Forecast, 2016-2026
11.5 Jardiance (Empagliflozin; Eli Lilly): Revenue Forecast, 2016-2026
12. Biguanides Market, 2016-2026
12.1 Biguanides Market, 2015
12.2 Biguanides: Revenue Forecast: 2016-2026
12.2.1 Biguanides: Market trends, 2016-2026
12.2.2 Metformin: Delay of Diabetes
12.2.3 Higher Mortality Associated with Combined Metformin and Insulin
12.3 Glucophage (Metformin; Merck (MSD)): Revenue Forecast, 2016-2026
12.4 Glumetza (Metformin Hydrochloride; Salix Pharmaceuticals): Revenue Forecast, 2016-2026
12.5 Fortamet (Metformin; Shionogi & Co): Revenue Forecast, 2016-2026
13. National Markets for Diabetes Drugs, 2016-2026
13.1 Leading National Markets for Diabetes Drugs, 2015
13.2 Leading National Diabetes Drugs Market: Revenue Forecast, 2016-2026
13.3 The US to Sustain its Market Leadership: Revenue Forecast 2016-2026
13.3.1 High Diabetes Prevalence within a Complex Healthcare System
13.4 The Japanese Market, Revenue Forecast, 2016-2026
13.4.1 Sanofi and Takeda Collaborate to Fight Diabetes in Japan
13.4.2 Novel Treatment Options in Japan
13.5 EU5 (Germany, France, UK, Italy, Spain) Market for Diabetes Drugs, 2015
13.5.1 The EU5 (Germany, France, UK, Italy, Spain) Market Revenue Forecasts, 2016-2026
13.5.2 Germany: Disease Treatment Measures Require Improvement – Revenue Forecast, 2016-2026
13.5.2.1 Tough Reimbursement Rules: More Data for Faster Approval?
13.5.3 French National Diabetes Market Revenue Forecast, 2016-2026
13.5.3.1 Great Standard of Care and Regulatory Reforms in France
13.5.4 The UK National Diabetes Market Revenue Forecast, 2016-2026
13.5.4.1 Faster Approvals for New Therapies in the UK
13.5.5 Italian National Diabetes Market Revenue Forecast, 2016-2026
13.5.6 Spanish National Diabetes Market Revenue Forecast, 2016-2026
13.6 China: The World’s Largest Diabetic Population – Revenue Forecast, 2016-2026
13.6.1 Presence of Multinational Companies and the Power of Buyers
13.6.2 Disparity in Regional Health Spending
13.6.3 Multi-Billion Dollar Investment to Improve Healthcare
13.7 The Indian Market: Revenue Forecast, 2016-2026
13.7.1 Focus on the Rural Population
13.8 The Russian National Diabetes Market, 2016-2026
13.8.1 High Out of Pocket Costs Reduce Compliance
13.9 Brazil: Improved Access to Care in Rural Areas – Revenue Forecast, 2016-2026
13.9.1 Localised Insulin Production in Brazil
13.9.2 Diabetes Awareness Initiatives will Increase Market Potential
14. Diabetes Drug Market R&D Pipeline, 2016
14.1 New Diabetes Drugs Approvals and Leading Companies’ Developments, 2015-2016
14.1.1 Novo Nordisk
14.1.2 Eli Lilly & Boehringer Ingelheim
14.1.3 AstraZeneca
14.2 Human Insulins and Analogues: New Approvals
14.2.1 Insulin Glargine (Basaglar, Eli Lilly and Boehringer Ingelheim): Receives US Approval After Delays
14.2.2 Insulin Glargine (Toujeo, Sanofi): Will it Replace Lantus?
14.2.3 Afrezza (Sanofi and MannKind): The First Inhaled Insulin Fails to Make an Impact
14.3 Human Insulins and Analogues: Pipeline Developments: New Approvals
14.3.1 Tresiba (Novo Nordisk): Opportunity Revival
14.3.2 MK-1293 (Merck (MSD) and Biogen Idec): Will Provide more Biosimilar Competition for Lantus
14.3.3 NN9924 (Novo Nordisk)
14.3.4 BIOD-123 (Biodel)
14.4 DPP-4 Inhibitors: Pipeline Developments
14.4.1 Zafatek (Trelagliptin Succinate; Takeda and Furiex Pharmaceuticals): Approved in Japan
14.4.2 Omarigliptin (MK-3102; Merck (MSD))
14.5 GLP-1: New Approvals and Pipeline, 2016
14.5.1 Trulicity (Dulaglutide; Eli Lilly): Potential for Blockbuster Status
14.5.2 Semaglutide (NN9535; Novo Nordisk)
14.5.3 Xultophy (IdegLira; Novo Nordisk)
14.5.4 ITCA 650 (Intarcia Theraputics)
14.6 Sodium Glucose Co-Transporter 2: Pipeline Developments, 2016
14.6.1 Sotagliflozin (Lexicon Pharmacuticals)
14.6.2 Apleway (Tofogliflozin; Sanofi/Takeda)
14.6.3 MK8835 (Ertugliflozin; Merck (MSD))
14.6.4 Bexagliflozin (Theracos)
14.7 Other Diabetes Drugs: Pipeline Developments, 2016
14.7.1 DM199 (DiaMedica)
14.7.2 Glucokinase Activators
14.7.2.1 LY2608204 (Eli Lilly and Yabao Pharmaceutical Inc.)
15. Diabetes Drugs: World Industry, Market and R&D Analysis, 2016-2026
15.1 SWOT Analysis of the Diabetes Drug Market, 2016-2026
15.2 Strengths
15.2.1 Promising Research and Development
15.2.2 Secondary Indications
15.2.3 Biological Drugs are Tougher to copy and Offer Variety
15.2.4 Market Competition
15.3 Weaknesses
15.3.1 Lack of Disease Awareness
15.3.2 Tougher Reimbursement Rules
15.3.3 Increased Risk of Cardiovascular Complications
15.3.4 Rising Cost of Drug Development
15.4 Opportunities
15.4.1 Rising Disease Prevalence
15.4.2 Emerging National Markets Hold Great Potential
15.4.3 Novel Insulin Delivery Methods
15.4.4 New Classes of Anti Diabetes Drugs
15.5 Threats
15.5.1 Type 1 Diabetes Vaccine
15.5.2 Increased Popularity of Other Therapies
15.5.3 Generic Drugs: Patent Expiries and Rising Competition
15.5.4 Regulatory Barriers – Challenges Getting Drug Approval
15.6 STEP Analysis of the World Diabetes Drugs Market, 2016-2026
15.6.1 Social Developments
15.6.2 Technological Advances
15.6.3 Economic Factors
15.6.4 Political Issues
16. Research Interviews
16.1 Interview with Professor Mark Baker, Clinical Practice Director of the National Institute of Healthcare Excellence (NICE)
17. Conclusions from the Research and Analysis
17.1 The Diabetes Market – Trends Shaping Those Treatments
17.2 Outlook of the Worlds Diabetes Drug Industry, 2016-2026
17.3 Insulin Will Continue to Dominate the Market
17.4 National Diabetes Market Outlooks, 2016-2026
17.5 Future Opportunities
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Report Evaluation Form
【レポート販売概要】
■ タイトル：糖尿病治療薬の世界市場2016-2026■ 英文：Diabetes World Drug Market Report 2016-2026
■ 発行日：2016年6月
■ 調査会社：visiongain
■ 商品コード：VGAIN60707
■ 調査対象地域：グローバル
- 世界の航空・防衛産業におけるEDA市場The global EDA in the aerospace and defense sector has started to grow at a faster rate due to the rising demand for semiconductor chips. Technavio’s market research analysts predict steady market growth with a CAGR of around 8% from 2015 to 2019. CAE emerged as the largest segment in the global EDA market in 2014. It includes ESL, RTL simulation, hardware-assisted verification, analysis tool, syn …
- 高血糖症（Hyperglycemia）：グローバル臨床試験レビュー（2014年上半期）Hyperglycemia Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Hyperglycemia Global Clinical Trials Review, H1, 2014" provides data on the Hyperglycemia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hyperglycemia. It includes an overview of the trial numbers and their recruitment status as per the …
- 芝生及び観賞植物用バイオスティミュラント（生物刺激剤）の世界市場Bio stimulants are used in turf and ornamentals to enhance root growth in turf. Using it, turf and ornamentals appear healthy and strong, thereby increasing bio stimulant usage from last few years. The Bio stimulants in turf and ornamentals market were valued at $ 2.2 billion in 2013, to grow at a CAGR of 11.4% annually to reach at $ 3.8 billion by 2018. It constitutes 20.0% of the global Bio stim …
- 暗号化ソフトウェアの世界市場：ディスク暗号化、ファイル/フォルダー暗号化、データベース暗号化、通信暗号化、クラウド暗号化The pervasive technological advancements such as mobility and cloud are considerably transforming the work ways in companies. In the past few years, businesses have extensively incorporated diverse technological progressions such as PCs, social media, cloud and mobility which have led to enlargement of data being generated across companies. This is evident from the widespread embracement of mobile …
- 自動車用アクティブシャシーシステムの世界市場2018-2022113 pages, November 2018 About this market The global automotive market is quickly evolving as the automobiles are becoming advanced due to the advances in automotive technology. An active chassis system is a dynamic chassis system that significantly improves the riding comfort and stability of the vehicle under varied external conditions. Therefore, such advantages and benefits associated with ac …
- ビスマスの世界市場動向2014/2015The report presents a thorough study of bismuth, covering both global and regional markets. It aims to give a proper picture of the market, its trends, perspectives and opportunities. Comprehensive data showing bismuth worldwide production, consumption, trade statistics and prices are provided. Each country’s market overview covers the following: bismuth production in the country, major manufactur …
- 世界のナノコンポジット市場：クレイ系、カーボンナノチューブ系About Nanocomposites Nanocomposites are a class of materials, which incorporate nano-sized particles in a matrix of other materials such as polymers. Such nano-sized particles enhance the properties of the matrix material, including characteristics such as mechanical strength, electrical and thermal conductivity, and chemical resistance. Nanocomposites are used in a range of industries such as Bui …
- 製造産業におけるビックデータ市場：主要動向、市場機会、市場予測The manufacturing industry is rapidly transforming as technology, competition, and the evolving demands of global consumers dictate the need for continuously improving efficiencies and flexibility. Significant impact from ICT include machine communications, teleoperation, and integration with the Internet of Things (IoT). It is anticipated that machine data will represent up to 8 Zeta bytes by 202 …
- 世界の新生児マススクリーニング検査市場（～2019）The global newborn screening market is categorized on the basis of test type, technology, product, and geography. The mass spectrometry market is expected to register the highest growth rate in the newborn screening market by technology, during the forecast period. This high growth is attributed to various nations opting for expanded newborn screening. Tandem mass spectrometry is a fundamental ins …
- 高等教育アクティブラーニング・プラットフォームの世界市場2016-2020About Educational Technology Educational technology is a means to enrich the learning experience. To that end, digital classrooms make use of advanced technological learning aids (such as interactive whiteboards and 3D printing) to boost student interactivity and to enhance knowledge retention. As a result, educational institutions have increased their budgets to include more collaboration, assess …
- 高機能ファブリックの世界市場：コーティング布、ポリアミド、ポリエステル、複合ファブリック、アラミドThe performance fabric market is projected to reach 79.55 Billion by 2020, registering a CAGR of 4.8% between 2015 and 2020. Increasing awareness regarding personal hygiene and physical fitness and advancement in performance fabric production technology are the major drivers of the market. The performance fabrics market is witnessing high growth on account of increasing demand from industrial, def …
- 薬局オートメーションの世界市場予測（～2022年）：薬剤分注装置、包装・ラベル装置、計数装置、保管装置The pharmacy automation market is expected to grow at a lucrative CAGR of 8.2% from 2017 to 2022, to reach USD 5.38 billion by 2022 from USD 3.63 billion in 2017. The growth in pharmacy automation market is primarily due to the increased focus on reducing medication errors, increased burden on pharmacies due to rising geriatric population, rapid decentralization of pharmacies, and rising labor cos …
- 爪真菌症(爪白癬)(Onychomycosis (Tinea Unguium))：世界の治験レビュー2014年下半期版Onychomycosis (Tinea Unguium) Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Onychomycosis (Tinea Unguium) Global Clinical Trials Review, H2, 2014" provides data on the Onychomycosis (Tinea Unguium) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Onychomycosis (Tinea Unguium). It includes an overv …
- 世界の医療技術市場：ソフトウェア・ソリューション、医療機器、画像診断機器About Medical Technologies Medical technology is a collective term for software solutions, medical devices, imaging and diagnostic equipment used to ensure good health. The Global Medical Technologies market covers active implantable technology, hospital hardware, anaesthetic and respiratory technology, In vitro diagnostics technology, dental technology, electromechanical medical technology, techn …
- 磁場センサーの世界市場展望2017-20276According to Stratistics MRC, the Global Magnetic Field Sensor market is accounted for $3.00 million in 2017 and is expected to reach $7.55 million by 2026 growing at a CAGR of 10.7%. Factors such as growth in automotive industry and endless growth in consumer electronics segment are driving the market. However, falling average selling prices (asps) of semiconductors & sensors is hampering the Mag …
